Headed up by experienced researchers in the fields of vascular biology, coagulation, and thrombotic diseases, Osciflex LLC was formed explictly to address the development of a medical device to prevent hospital-acquired thrombosis. Anchored in patents held by University of Pennsylvania, principals of the firm diiscovered the molecular pathways relating blood flow pattern to endothelial gene expression of thrombosis related proteins. They then outlined a protocol to analyze venous valve oscillatory flow in human subjects using vascular ultrasound, and created the initial OsciFlex device design. Blood clots can form in the veins of patients with various clinical conditions and can result in a pulmonary embolism that cause death or increase hospital stays that, in turn, increase incurred costs. Effectively imitating natures process to prevent deadly blood clots, Osciflex is bringing to use-condition products using novel science and design thinking to help prevent hospital acquired VTE/DVT/PE: a more effective compression therapy device better to prevent Venous thromboembolism (VTE) in patients, reduce the use of expensive and risky anti-coagulation pharmaceuticals.
